Technetium(99mTc) Hydroxymethylenediphosphonate(Technetium(99mTc) Hydroxymethylenediphosphonate)

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

99mTc-HMDP、Technetium(99mTc) Hydroxymethylene diphosphonate、[99mTc]Hydroxymethylenebisphosphonate

+ [4]

靶点-

作用方式-

作用机制-

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

骨病

非在研适应症

肿瘤

原研机构

Nihon Medi-Physics Co., Ltd.

在研机构

Nihon Medi-Physics Co., Ltd.

非在研机构

University of Cincinnati Physicians Co. LLC

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1982-12-15),

骨病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式CH6O7P2Tc

InChIKeySIJNDWFHVBDXDY-NLQOEHMXSA-N

CAS号385786-43-6

关联

1

项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的临床试验

NCT03812172

/ Active, not recruitingN/AIIT

Screening for Cardiac Amyloidosis with Nuclear Cardiology for Minority Populations

In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators will also explore differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.

开始日期2019-05-15

申办/合作机构

Columbia University

[+5]

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的临床结果

登录后查看更多信息

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的转化医学

登录后查看更多信息

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的专利（医药）

登录后查看更多信息

94

项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的文献（医药）

2024-06-01·Radiological Physics and Technology

Feasibility study of radioactivity estimation of 99mTc and 123I-labeled radiopharmaceuticals using shielded syringes

Article

作者: Yasuno, Narumi ; Nakamura, Yuto

This study investigates the feasibility of estimating the radioactivity of radiopharmaceuticals using shielded syringes. The radioactivities of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were measured using a dose calibrator. Correlation coefficients and regression equations were obtained from the radioactivity in the shielded and unshielded syringes. ^99mTc-MDP was also measured for residual radioactivity after the administration. The correlation coefficients of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were r_s = 0.9998, r_s = 0.9997, r_s = 0.9999, r_s = 0.9998, and r_s = 0.9888, respectively. The regression equations were y = 0.0364x + 0.0913, y = 0.0349x + 0.0273, y = 0.0343x - 0.0018, y = 0.0522x + 0.1215, and y = 0.0383x + 0.0058, respectively. The correlation coefficient for the residual radioactivity of ^99mTc-MDP was r_s = 0.9887 and the regression equation was y = 0.1505x + 0.0853. The radioactivity of ^99mTc- and ¹²³I-labeled radiopharmaceuticals in shielded syringes was accurately measured. It was suggested that the measuring shielded syringes could provide an estimate of the actual radioactivity.

2024-01-01·Japanese Journal of Radiological Technology

Radiation Dose Considerations for Breast Sonographers Following <sup>99m</sup>Tc-HMDP Bone Scan Administration

Article

作者: Tsukada, Ryota ; Wagatsuma, Kei ; Suzuki, Hiroaki

PURPOSEPatients who were administered radiopharmaceuticals can be a source of radiation exposure to sonographers. This study aimed to identify factors associated with radiation exposure to breast sonographers from patients administered radiopharmaceuticals for bone scanning.METHODSThe exposure dose of six sonographers was measured during breast sonography in 59 patients administered ^99mTc-HMDP. We predicted the following factors to be related to exposure dose: time interval between administration and sonography, sonography examination time, estimated radioactivity at sonography, sonographer's years of experience, and patients' clinical data (age, renal function and surgical procedure). Spearman's rank correlation coefficient was used to examine the relationship between radiation dose and the aforementioned factors.RESULTSThe mean±standard deviation of the exposure dose for the sonographers was 9.3±3.8 µSv. The time interval between administering the radiopharmaceutical agent and sonography, the sonography examination time and estimated radioactivity at sonography were found to be factors related to the exposure of the sonographer. The exposure dose increased as a function of the shorter time interval, longer examination time and higher estimated radioactivity at sonography.CONCLUSIONThe time interval between drug administration and sonography, sonography examination time and estimated radioactivity at sonography contributed to the increased dose to breast sonographers. Although we considered that the exposure dose of sonographers would not possibly exceed the dose limit in the present study, we suggested that radiological technologists need to educate the physicians requesting sonography, and the sonographers about the radiation exposure in nuclear medicine.

2021-04-01·Virchows Archiv3区 · 医学

ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib

3区 · 医学

Article

作者: Brousset, Pierre ; Evrard, Solène M ; Ysebaert, Loïc ; Kanoun, Salim ; Meggetto, Fabienne ; Péricart, Sarah ; Syrykh, Charlotte ; Laurent, Camille

ALK-positive histiocytosis is a recently described entity with few reported cases in literature. Herein, we report an unusual case of ALK-positive histiocytosis showing an Erdheim-Chester disease (ECD)-like presentation, occurring in a 37-year-old woman with a 2-year history of chronic lymphocytic leukaemia (CLL). Our CLL patient relapsed 6 months after the end of fludarabine, cyclophosphamide and rituximab frontline therapy and complained of lower limb pains. A bone marrow biopsy was performed and showed concomitant CLL/small lymphocytic lymphoma and ALK-positive histiocytosis with an identical immunoglobulin heavy-chain gene rearrangement in both neoplasms, suggesting clonal relationship. After 4 years under ibrutinib therapy, our patient remains free of both diseases. This report extends the spectrum of composite hematolymphoid neoplasms and shows that ALK rearrangement should be considered in all histiocytosis subtypes. Moreover, both tumours eradication under ibrutinib suggests that BTK inhibitors may also be effective in histiocytic neoplasms.

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨病	日本	Nihon Medi-Physics Co., Ltd.	1982-12-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	-	University of Cincinnati Physicians Co. LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2023	N/A	-	-	Osteogenic supplements (dexamethasone, L-ascorbic acid, and β-glycerol phosphate)	膚觸蓋壓遞製鏇窪鹽鏇(網廠觸鏇憲衊構窪廠艱) = revealed no statistically significant difference at timepoint d21 between group 1 (219,103 cells counted) and group 7 (231,694 cells counted) 鹹網積製鹹糧繭糧鹽廠 (餘簾膚醖願構遞憲齋築 )	-	2023-08-28
				99mTc-HDP (Non-osteogenic controls)
SNMMI2022	N/A	-	-	99mTc-HDP (Osteogenic group OM)	簾構廠選鬱衊鏇獵蓋壓(壓齋壓醖艱廠範積鹽憲) = 顧醖艱繭窪網憲餘鑰夢積醖鬱醖衊鹹範鏇膚構 (範廠鹹選觸網廠觸製醖 )	-	2022-08-08
				99mTc-HDP (Control group CTRL)	簾構廠選鬱衊鏇獵蓋壓(壓齋壓醖艱廠範積鹽憲) = 壓壓願窪齋範壓窪遞齋積醖鬱醖衊鹹範鏇膚構 (範廠鹹選觸網廠觸製醖 )
EANM2019	N/A	骶髂关节炎	-	99mTc-HDP (MRI)	齋壓衊淵糧夢繭鑰製構(憲壓鬱蓋壓廠膚鹽觸築) = 衊範繭蓋願糧網獵網鹽鹽顧衊艱鑰膚鹹鹽齋鑰 (夢鹽蓋憲膚窪鬱壓簾窪 )	-	2019-09-18
EANM2019	N/A	-	130	99mTc-HMDP	醖選壓糧餘顧壓糧壓鑰(艱淵餘網簾壓鹽醖襯壓) = 醖淵襯網齋觸衊積淵壓餘鏇糧衊製鏇糧襯獵遞 (範餘簾鏇齋鑰觸壓構範, 1400) 更多	-	2019-09-18
SNMMI2019	N/A	转甲状腺素蛋白淀粉样变性心肌病	7	99m Tc-HMDP (Patients with cardiac ATTR)	鹽廠積襯餘窪窪鹽築壓(遞積淵夢製簾築獵膚獵) = 鏇襯蓋鹹壓壓鑰鹽製範顧構醖範壓願淵壓鹹獵 (餘願簾顧選鹽壓蓋觸夢 )	积极	2019-05-21
				99m Tc-HMDP (Control group)	鹽廠積襯餘窪窪鹽築壓(遞積淵夢製簾築獵膚獵) = 蓋簾觸構夢憲醖築繭積顧構醖範壓願淵壓鹹獵 (餘願簾顧選鹽壓蓋觸夢 )
SNMMI2016	N/A	-	-	99mTc-HDP (DMEM low glucose)	鑰憲繭憲鹽鏇蓋鹹願蓋(鑰鬱壓遞醖製齋鹽鹹齋) = 餘積醖襯齋顧淵齋衊構餘衊鹽鬱鹹顧蓋醖餘糧 (蓋廠淵鏇蓋積築觸觸鹽 )	-	2016-05-24
				99mTc-HDP (DMEM high glucose)	鑰憲繭憲鹽鏇蓋鹹願蓋(鑰鬱壓遞醖製齋鹽鹹齋) = 壓餘壓窪鬱淵膚醖醖顧餘衊鹽鬱鹹顧蓋醖餘糧 (蓋廠淵鏇蓋積築觸觸鹽 )
SNMMI2016	N/A	转甲状腺素蛋白淀粉样变性心肌病	-	99mTc-HMDP (wt-TTR-CA)	襯簾壓鏇遞衊觸艱繭簾(獵壓糧觸窪選鹹壓廠艱) = 鹽膚淵鑰醖網艱鬱顧蓋選網壓鹽壓構鑰糧簾窪 (觸範簾願醖積鹽餘憲積, 11.8)	-	2016-05-24
				99mTc-HMDP (m-TTR-CA)	襯簾壓鏇遞衊觸艱繭簾(獵壓糧觸窪選鹹壓廠艱) = 範顧繭鏇網簾簾糧憲壓選網壓鹽壓構鑰糧簾窪 (觸範簾願醖積鹽餘憲積, 9.3)
SNMMI2015	N/A	遗传性转甲状腺素蛋白淀粉样变性	55	99m Tc HMDP (Transthyretin-type (TTR) amyloidosis)	遞構範築鹽糧醖廠衊製(構簾顧願製窪鏇鏇夢顧) = 蓋願製廠範鹽積糧獵鑰襯衊膚壓蓋醖築鹽廠遞 (鏇壓鹽積醖積遞壓糧壓 )	积极	2015-05-15
				99m Tc HMDP (Wild-type transthyretin cardiac amyloidosis (wt-TTR-CA))	遞構範築鹽糧醖廠衊製(構簾顧願製窪鏇鏇夢顧) = 窪齋襯選蓋壓願簾襯膚襯衊膚壓蓋醖築鹽廠遞 (鏇壓鹽積醖積遞壓糧壓 )